Publications by authors named "Peter Spacciapoli"

Claim this Profile
C
Comprehensive Strategies to Bicyclic Prolines: Applications in the Synthesis of Potent Arginase Inhibitors.
Derun Li, Hongjun Zhang, Thomas W Lyons, Min Lu, Abdelghani Achab, Peter Spacciapoli

ACS Med Chem Lett· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology.
Min Lu, Hongjun Zhang, Derun Li, Matthew Childers, Qinglin Pu, Peter Spacciapoli

ACS Med Chem Lett· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carbamate and -Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors.
Derun Li, Yongqi Deng, Abdelghani Achab, Indu Bharathan, Brett Andrew Hopkins, Peter Spacciapoli

ACS Med Chem Lett· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategic Incorporation of Polarity in Heme-Displacing Inhibitors of Indoleamine-2,3-dioxygenase-1 (IDO1).
Catherine White, Meredeth A McGowan, Hua Zhou, Nunzio Sciammetta, Xavier Fradera, Peter Spacciapoli

ACS Med Chem Lett· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Brain Penetrant Mutant IDH1 Inhibitor Provides In Vivo Survival Benefit.
Johnny Kopinja, Raquel S Sevilla, Diane Levitan, David Dai, Amy Vanko, Peter Spacciapoli

Sci Rep· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers.
Jongwon Lim, Elizabeth H Kelley, Joey L Methot, Hua Zhou, Alessia Petrocchi, Peter Spacciapoli

J Med Chem· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors.
Dong Xiao, Anandan Palani, Xianhai Huang, Michael Sofolarides, Wei Zhou, Peter Spacciapoli

Bioorg Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Hit-to-Lead Optimization of Non-ATP Competitive MK2 (MAPKAPK2) Inhibitors.
Xiaohua Huang, Gerald W Shipps, Cliff C Cheng, Peter Spacciapoli, Xingmin Zhang

ACS Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and characterization of orthosteric and allosteric muscarinic M2 acetylcholine receptor ligands by affinity selection-mass spectrometry.
Charles E Whitehurst, Naim Nazef, D Allen Annis, Yongmin Hou, Denise M Murphy, Peter Spacciapoli

J Biomol Screen· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histatin-derived peptides: potential agents to treat localised infections.
David M Rothstein, Eva J Helmerhorst, Peter Spacciapoli, Frank G Oppenheim, Phillip Friden

Expert Opin Emerg Drugs· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis